Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Management

BioVaxys Announces Application for Management Cease Trade Order

By The Northwire Desk — AI Analysis Mar 03, 2026 · 16:30 BIOV · 0.13 BioVaxys Technology Corp.
BIOV · Price

Executive Summary

  • BioVaxys Technology Corp. missed the February 28, 2026 deadline to file its annual financial statements and related MD&A for the year ended October 31, 2025.
  • The company applied for and received a temporary Management Cease‑Trade Order (MCTO) effective March 3, 2026, restricting trading by CEO James Passin and CFO Christopher Cherry until the filings are completed.
  • BioVaxys expects to complete the audit and file the outstanding annual reports by April 28, 2026 and will issue bi‑weekly status updates as required under NP 12‑203.

Key Details

  • Missed filing deadline: February 28, 2026 (annual financial statements, MD&A, certifications).
  • Reason for delay: Late start to the audit caused by changes to accounting systems and processes.
  • Audit completion target: April 28, 2026.
  • MCTO filing: Application submitted to the British Columbia Securities Commission; MCTO granted effective March 3, 2026.
  • Restrictions under MCTO: Prohibits trading in BioVaxys securities by CEO James Passin and CFO Christopher Cherry until filings are filed.
  • Compliance obligations: Company will follow alternative information guidelines under NP 12‑203, issuing bi‑weekly default status reports via news releases while the annual filings remain outstanding.
  • Future filing expectation: Annual financial statements and related documents to be filed as soon as possible after audit completion, no later than April 28, 2026.

Notable Quotes

“The Company believes that the audit will be completed by April 28, 2026, with the annual filings to be completed as soon as possible thereafter.” – James Passin, CEO

Materiality Assessment: Material – Negative (the delay and trading restrictions could affect investor perception and share liquidity).

Read the original news release →

More from BioVaxys Technology Corp.

May 01, 2026 · 08:01

BioVaxys Preclinical Validation Amidst Compliance Overhang and Liquidity Constraints

Other Apr 28, 2026 · 16:30

BioVaxys Shares Plunge as Filing Default Extends Amidst Clinical Progress

Regulatory Apr 27, 2026 · 08:01

BioVaxys Shares Plunge Amid Compliance Risks Despite ASCO Presentation

Other Apr 13, 2026 · 16:35

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Regulatory Mar 10, 2026 · 08:00

BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines

Other Jan 29, 2026 · 08:00

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

Other